
Linagliptin (2.5mg) + Metformin (500mg)
Active composition
+1 more active ingredient
Linagliptin inhibits the enzyme DPP-4, leading to increased levels of incretin hormones, which promote insulin secretion and inhibit glucagon release, thereby lowering blood glucose levels.
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Medical applications
Linares M Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Linagliptin 2.5 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby contributing to better glycemic control. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these two agents provides effective control of blood glucose levels, reducing both fasting and postprandial hyperglycemia. Linares M Tablet is typically prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve target glycemic levels. It is important to monitor renal function prior to and during treatment, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Linagliptin is generally well tolerated with a low risk of hypoglycemia. Patients should be advised to adhere to prescribed dosing and lifestyle modifications to optimize therapeutic outcomes.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Linares M Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Linares M Tablet is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Medical Advice
There is limited information available on the use of Linares M Tablet in patients with kidney disease. Please consult your doctor.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
There is limited information available on the use of Linares M Tablet in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Linares M Tablet

Metformin (500mg) + Linagliptin (2.5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Linagliptin inhibits the enzyme DPP-4, leading to increased levels of incretin hormones, which promote insulin secretion and inhibit glucagon release, thereby lowering blood glucose levels.
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Medical applications
Linares M Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Linagliptin 2.5 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby contributing to better glycemic control. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these two agents provides effective control of blood glucose levels, reducing both fasting and postprandial hyperglycemia. Linares M Tablet is typically prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve target glycemic levels. It is important to monitor renal function prior to and during treatment, as Metformin is contraindicated in patients with significant renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Linagliptin is generally well tolerated with a low risk of hypoglycemia. Patients should be advised to adhere to prescribed dosing and lifestyle modifications to optimize therapeutic outcomes.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Linares M Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Linares M Tablet is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Medical Advice
There is limited information available on the use of Linares M Tablet in patients with kidney disease. Please consult your doctor.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
There is limited information available on the use of Linares M Tablet in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Linares M Tablet













